Short answer
CYTOKINETICS INC (CYTK) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $19M (up 1125.8% year over year) with net income of −$206M.
Q1 2026 key financials · XBRL
- Revenue
- $19M
- +1125.8% YoY
- Net income
- −$206M
- −27.7% YoY
- Operating margin
- -948.7%
- EPS (diluted)
- −$1.67
- −22.8% YoY
Source: XBRL data from the CYTOKINETICS INC (CYTK) Q1 2026 10-Q on SEC EDGAR. USD.
CYTOKINETICS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- MYQORZO launched commercially in U.S. Q1 2026
- ACACIA-HCM met dual primary endpoints; LVEF <50% in 10% vs 1% placebo
- EU commercialization expected in Q2 2026; CEDAR-HCM enrollment completion expected Q4 2026
Risk Factors
- Newly added tariff risk triggered by April 2026 Pharmaceutical Tariffs, potentially raising costs for imported pharmaceutical inputs
- Most material operational update: FDA workforce reductions, including 3,500 eliminated positions, potentially delaying regulatory reviews
- Regulatory compliance exposure: MYQORZO REMS requires certified pharmacies, prescriber record-keeping, monitoring, and patient counseling
- Near-term commercial risk: inadequate payor coverage or reimbursement could limit MYQORZO adoption and profitability
- Supply concentration: single-source CMOs manufacture MYQORZO finished product and active pharmaceutical ingredient
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CYTOKINETICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.